Stock Scorecard



Stock Summary for Astrazeneca plc (AZN) - $187.98 as of 5/1/2026 7:09:24 PM EST

Total Score

10 out of 30

Safety Score

52 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AZN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AZN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AZN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AZN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AZN (52 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for AZN

Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. 5/2/2026 8:39:00 AM
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer 5/1/2026 2:10:00 PM
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE 5/1/2026 2:10:00 PM
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer 5/1/2026 12:22:00 PM
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters 5/1/2026 12:10:00 PM
AstraZeneca PLC expected to post earnings of $2.58 a share - Earnings Preview 5/1/2026 8:10:00 AM
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer 4/30/2026 7:39:00 PM
Jennison Associates LLC Has $309.15 Million Holdings in Astrazeneca Plc $AZN 4/30/2026 7:10:00 PM
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom 4/30/2026 6:09:00 PM
FDA panel votes against backing AstraZeneca's breast cancer drug 4/30/2026 6:08:00 PM

Financial Details for AZN

Company Overview

Ticker AZN
Company Name Astrazeneca plc
Country N/A
Description AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 12/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 187.98
Price 4 Years Ago 124.65
Last Day Price Updated 5/1/2026 7:09:24 PM EST
Last Day Volume 4,443,017
Average Daily Volume 2,053,083
52-Week High 210.50
52-Week Low 130.04
Last Price to 52 Week Low 44.56%

Valuation Measures

Trailing PE N/A
Industry PE 18.46
Sector PE 85.51
5-Year Average PE 62.47
Free Cash Flow Ratio 38.52
Industry Free Cash Flow Ratio 36.48
Sector Free Cash Flow Ratio 26.30
Current Ratio Most Recent Quarter 0.91
Total Cash Per Share 4.88
Book Value Per Share Most Recent Quarter 31.38
Price to Book Ratio 6.05
Industry Price to Book Ratio 6.16
Sector Price to Book Ratio 5.71
Price to Sales Ratio Twelve Trailing Months 4.93
Industry Price to Sales Ratio Twelve Trailing Months 3.71
Sector Price to Sales Ratio Twelve Trailing Months 27.97
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 1,550,284,000
Market Capitalization 291,422,386,320
Institutional Ownership N/A

Dividends

Ex-Dividend Date 2/20/2026
Previous Dividend Amount 0.7670
Current Dividend Amount 1.5950
Total Years Dividend Increasing 1
Trailing Annual Dividend Rate 2.36
Trailing Annual Dividend Yield 1.26%
Forward Annual Dividend Rate 3.19
Forward Annual Dividend Yield 1.70%
5-Year Dividend Payments Count 10
3-Year Average Dividend Yield 1.36%
5-Year Average Dividend Yield 1.71%
1-Year Dividend Growth Rate Percentage 30.36%
3-Year Dividend Growth Rate Percentage 14.18%
5-Year Dividend Growth Rate Percentage 9.52%
All-Time Dividend Growth Rate Percentage 4.11%
Dividend Payout Ratio 36.17%

Income Statement

Quarterly Earnings Growth YOY 53.90%
Annual Earnings Growth 45.77%
Reported EPS 12 Trailing Months 6.53
Reported EPS Past Year 4.81
Reported EPS Prior Year 4.59
Net Income Twelve Trailing Months 11,554,000,000
Net Income Past Year 10,255,000,000
Net Income Prior Year 7,035,000,000
Quarterly Revenue Growth YOY 4.10%
5-Year Revenue Growth 17.15%
Operating Margin Twelve Trailing Months 21.60%

Balance Sheet

Total Cash Most Recent Quarter 7,560,000,000
Total Cash Past Year 5,711,000,000
Total Cash Prior Year 5,488,000,000
Net Cash Position Most Recent Quarter -16,894,000,000
Net Cash Position Past Year -19,004,000,000
Long Term Debt Past Year 24,715,000,000
Long Term Debt Prior Year 26,506,000,000
Total Debt Most Recent Quarter 24,454,000,000
Equity to Debt Ratio Past Year 0.66
Equity to Debt Ratio Most Recent Quarter 0.66
Total Stockholder Equity Past Year 48,667,000,000
Total Stockholder Equity Prior Year 40,786,000,000
Total Stockholder Equity Most Recent Quarter 47,333,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 9,108,512,943
Free Cash Flow Per Share Twelve Trailing Months 5.88
Free Cash Flow Past Year 11,765,000,000
Free Cash Flow Prior Year 7,275,000,000

Options

Put/Call Ratio 1.10
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.28
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 5/1/2026 6:05:39 PM EST